Abstracts tagged "disease-modifying antirheumatic drugs and psoriatic arthritis"

Abstract Number: 2478 • ACR/ARP Annual Meeting 2019
Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan
Daniel Aletaha¹, Patrick Zueger ², Naijun Chen ² and Nicola Booth ³, ¹Medical University of Vienna, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Enthesitis, a symptom commonly associated with psoriatic arthritis (PsA), negatively affects quality of life. Although enthesitis is routinely reported in randomized clinical trials of…
Abstract Number: 2143 • ACR/ARHP Annual Meeting 2018
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Linh Truong¹ and Maida Wong², ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Division of Rheumatology, University of California, Irvine, Orange, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…
Abstract Number: 2217 • ACR/ARHP Annual Meeting 2012
Even After Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients
Frank Behrens¹, Michaela Koehm¹, Diamant Thaci², Brigitte Krummel-Lorenz³, Gerd Greger⁴, Bianca Wittig⁴ and Harald Burkhardt⁵, ¹CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ²Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, ³CIRI/Endokrinologikum, Frankfurt/Main, Germany, ⁴Abbott GmbH & Co KG, Wiesbaden, Germany, ⁵CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Frankfurt/Main, Germany
Background/Purpose: For the treatment of patients with psoriatic arthritis (PsA) only antiTNF biologics are licensed. Therefore, failures to anti-TNF are often switched to a different…